Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
7 "Se-Il Go"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer
Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Cancer Res Treat. 2019;51(4):1411-1419.   Published online February 25, 2019
DOI: https://doi.org/10.4143/crt.2018.663
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We previously demonstrated that CD44v9 and Ki-67 played an important role in predicting poor prognosis of early gastric cancer (EGC). However, little is known about combined use of both biomarkers as prognostic biomarker. The present study was performed to investigate the significance of CD44v9 and Ki-67 expression as a combination biomarker for EGC.
Materials and Methods
With tissue microarray for 158 EGC tissues, we performed immunohistochemical staining for CD44v9 and Ki-67. The whole patients were divided into three groups (group A, CD44v9- negative/Ki-67–low; group B, neither group A or C; and group C, CD44v9-positive/Ki-67– high). Its clinical significance was re-analyzed with adjustment via propensity score matching (PSM). For validation, we performed bootstrap resampling.
Results
The median follow-up duration was 90.4 months (range, 3.7 to 120.4 months). In the comparison according to CD44v9/Ki-67 expression, the combined use of the two biomarker clearly separated the three groups by 5-year survival rates (5-YSR, 96.3%, 89.8%, and 76.8% in group A, B, and C, respectively; p=0.009). After PSM, 5-YSR were 97.7% and 76.8% in group A+B and group C, respectively (p=0.002). Multivariable analysis demonstrated that group C had independently poor prognosis (hazard ratio, 9.137; 95% confidence interval, 1.187 to 70.366; p=0.034) compared with group A. Bootstrap resampling internally validated this result (p=0.016).
Conclusion
This study suggests that both positive CD44v9 and high Ki-67 expression are associated with poor prognosis in EGC, and the combined use of these markers provides better prognostic stratification than the single use of them.

Citations

Citations to this article as recorded by  
  • The Prognostic Importance of Ki-67 in Gastrointestinal Carcinomas: A Meta-analysis and Multi-omics Approach
    Mahdieh Razmi, Fatemeh Tajik, Farideh Hashemi, Ayna Yazdanpanah, Fatemeh Hashemi-Niasari, Adeleh Divsalar
    Journal of Gastrointestinal Cancer.2024; 55(2): 599.     CrossRef
  • Impact of Alcian blue and periodic acid Schiff expression on the prognosis of gastric signet ring cell carcinoma
    Juan Lin, Zhu-Feng Chen, Guo-Dong Guo, Xin Chen
    World Journal of Gastrointestinal Oncology.2024; 16(3): 687.     CrossRef
  • Significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues
    Su-nan Wang, Yang-kun Wang, Chao-ya Zhu, Bo Jiang, Dong-feng Ge, Ying-ying Li
    Clinical and Translational Oncology.2024; 27(1): 126.     CrossRef
  • Downregulation of MTHFD2 Inhibits Proliferation and Enhances Chemosensitivity in Hepatocellular Carcinoma via PI3K/AKT Pathway
    Jie Wang, Ze Yu, Yixiao Jiang, Ting Le, Yixin Wu, Ziqi Li, Guoqiang Zhang, Feiyue Wu, Haijie Ma
    Frontiers in Bioscience-Landmark.2024;[Epub]     CrossRef
  • Analysis of risk factors for lymph node metastasis and prognosis study in patients with early gastric cancer: A SEER data-based study
    Jinzhou Li, Ting Cui, Zeping Huang, Yanxi Mu, Yalong Yao, Wei Xu, Kang Chen, Haipeng Liu, Wenjie Wang, Xiao Chen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Revisiting therapeutic strategies for ovarian cancer by focusing on redox homeostasis (Review)
    Hiroshi Kobayashi, Shogo Imanaka, Hiroshi Shigetomi
    Oncology Letters.2022;[Epub]     CrossRef
  • Cyclin D1 Serves as a Poor Prognostic Biomarker in Stage I Gastric Cancer
    Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
    Current Issues in Molecular Biology.2022; 44(3): 1395.     CrossRef
  • Analysis of Endoscopy Findings to Identify Early Gastric Cancers with Tumor Budding: A Retrospective Study
    Lanqing Cao, Zhaoyong Wang, Liwei Duan, Lijuan Wei
    Journal of Gastrointestinal Surgery.2021; 25(7): 1706.     CrossRef
  • Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma
    Jinbo Song, Zhe Yu, Bingqi Dong, Mingkai Zhu, Xiaofeng Guo, Yongkang Ma, Shiming Zhao, Tiejun Yang
    World Journal of Surgical Oncology.2021;[Epub]     CrossRef
  • Fascin‑1 is associated with recurrence in solitary fibrous tumor/hemangiopericytoma
    Yumiko Yamamoto, Yoshihiro Hayashi, Hideyuki Sakaki, Ichiro Murakami
    Molecular and Clinical Oncology.2021;[Epub]     CrossRef
  • Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer
    Jie Yang
    Medical Oncology.2020;[Epub]     CrossRef
  • Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression
    Jinfen Wei, Meiling Hu, Kaitang Huang, Shudai Lin, Hongli Du
    International Journal of Molecular Sciences.2020; 21(17): 5983.     CrossRef
  • 7,943 View
  • 180 Download
  • 14 Web of Science
  • 12 Crossref
Close layer
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study
So-Yeon Jeon, Hye Sook Han, Woo Kyun Bae, Moo-Rim Park, Hyeok Shim, Sang-Cheol Lee, Se-Il Go, Hwan Jung Yun, Yong-Jin Im, Eun-Kee Song
Cancer Res Treat. 2019;51(1):90-97.   Published online February 27, 2018
DOI: https://doi.org/10.4143/crt.2017.577
AbstractAbstract PDFPubReaderePub
Purpose
Data on the efficacy of olanzapine in patients receiving moderately emetogenic chemotherapy (MEC) are limited. This study aimed to evaluate and compare the efficacy of olanzapine versus placebo in controlling nausea and vomiting in patients receiving MEC.
Materials and Methods
We conducted a randomized, double-blind, placebo-controlled study to determine whether olanzapine can reduce the frequency of chemotherapy-induced nausea and vomiting (CINV) and improve the quality of life (QOL) in patients receiving palonosetron and dexamethasone as prophylaxis for MEC-induced nausea and vomiting. The primary end point was complete response for the acute phase (0-24 hours after chemotherapy). The secondary end points were complete response for the delayed (24-120 hours) and overall phase (0-120 hours), proportion of significant nausea (visual analogue scale ≥ 25 mm), use ofrescue medications, and effect on QOL.
Results
Fifty-six patients were randomized to the olanzapine (n=29) and placebo (n=27) groups. Complete response rates were not significantly different between the olanzapine and placebo groups in the acute (96.5% vs. 88.0%, p=0.326), delayed (69.0% vs. 48.0%, p=0.118), and overall phases (69.0% vs. 48.0%, p=0.118). However, the percentage of patients with significant nausea (17.2% vs. 44.0%, p=0.032) and the use of rescue medications (0.03±0.19 vs. 1.88±2.88, p=0.002) were lower in the olanzapine group than in the placebo. Furthermore, the olanzapine group demonstrated better QOL (p=0.015).
Conclusion
Olanzapine combined with palonosetron and dexamethasone significantly improved QOL and vomiting control among previously untreated patients receiving MEC, although the efficacy was limited to the reduction of the frequency of CINV.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology
    Kazuhisa Nakashima, Saki Harashima, Rena Kaneko, Ryuhei Tanaka, Masakazu Abe, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Eriko Satomi, Masayuki Takeda, Takako Eguchi Nakajima, Naoki
    International Journal of Clinical Oncology.2025; 30(1): 17.     CrossRef
  • 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients
    Samantha K. F. Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko, Flay Charbonneau, Katie Wang, Mark Pasetka, Yoo-Joung Ko, Henry C. Y. Wong, Adrian Wai Chan, Thenugaa Rajeswaran, Milena Gojsevic, Edward Chow, Richard J. Gralla, Ter
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy
    Jing Shen, Juan Zhao, Gaowa Jin, Hui Li, Ying Jiang, Yungaowa Wu, Jiali Gao, Feng Chen, Jiaxuan Li, Wenjuan Wang, Quanfu Li
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Health-Related Quality of Life and Economic Analysis of Olanzapine Versus Aprepitant in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Malaysia
    Nurul Suhaida Badarudin, Noraida Mohamed Shah, Nurul Ain Mohd Tahir, Azmi Nor Mohd Farez Ahmat, Fuad Ismail, Farida Islahudin, Suhana Yusak, Syahir Muhammad, Kamarun Neasa Begam Mohd Kassim
    Value in Health Regional Issues.2024; 44: 101028.     CrossRef
  • Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy
    Vikas Ostwal, Anant Ramaswamy, Sarika Mandavkar, Prabhat Bhargava, Deepali Naughane, Sharon Flavia Sunn, Sujay Srinivas, Akhil Kapoor, Bal Krishna Mishra, Anuj Gupta, Bipinesh Sansar, Vikash Pal, Aparajita Pandey, Avinash Bonda, Indraja Siripurapu, Vamshi
    JAMA Network Open.2024; 7(8): e2426076.     CrossRef
  • Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clin
    Kazuhisa Nakashima, Ayako Yokomizo, Michiyasu Murakami, Kenji Okita, Makoto Wada, Keiko Iino, Tatsuo Akechi, Hirotoshi Iihara, Chiyo K. Imamura, Ayako Okuyama, Keiko Ozawa, Yong-il Kim, Hidenori Sasaki, Eriko Satomi, Masayuki Takeda, Ryuhei Tanaka, Takako
    International Journal of Clinical Oncology.2024; 29(12): 1785.     CrossRef
  • Can olanzapine preserve life quality in cancer patients undergoing abdominal radiation therapy?
    Meenu Vijayan, Sherin Joseph, Haridas M Nair, Debnarayan Dutta, M.P. Narmadha
    Medical Hypotheses.2023; 171: 111014.     CrossRef
  • Chemotherapy: how to reduce its adverse effects while maintaining the potency?
    Brianna, Sau Har Lee
    Medical Oncology.2023;[Epub]     CrossRef
  • The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
    Aziz Eghbali, Tahereh Bagherloo, Ali Ghasemi, Roghayeh R. Afzal, Aygin Eghbali, Kazem Ghaffari
    Advanced Biomedical Research.2023;[Epub]     CrossRef
  • Olanzapine treatment effectively relieves breakthrough chemotherapy-induced nausea and vomiting: a real-world experience
    Akihiro Uchiike, Haruka Kono, Katsuhiro Miura, Tatsuya Hayama, Daisuke Tsutsumi, Shinya Tsuboi, Susumu Ohtsuka, Shinji Hidaka
    Journal of Pharmaceutical Health Care and Sciences.2023;[Epub]     CrossRef
  • Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study
    Rony Dev, Linda L. Zhong, Abdulrazzak Zarifa, Aya A. Albittar, Laura Rubin, Suyu Liu, Timothy A. Yap, Shalini Dalal, David Hui, Daniel D. Karp, Apostolia M. Tsimberidou, Sarina A. Piha-Paul, Jordi Rodon Ahnert, Siqing Fu, Funda Meric-Bernstam, Aung Naing
    Investigational New Drugs.2022; 40(1): 124.     CrossRef
  • Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis
    Priya Patel, Paula D. Robinson, Nora Wahib, Patrick Cheung, Thomas Wong, Sandra Cabral, Arden Parker, Marie Cohen, Katie Devine, Paul Gibson, Mark T. Holdsworth, Eloise Neumann, Andrea Orsey, Robert Phillips, Daniela Spinelli, Jennifer Thackray, Marianne
    Supportive Care in Cancer.2022; 30(11): 8855.     CrossRef
  • Ջոակինո Ռոսինիի «Stabat Mater»-ը Հովհաննես Չեքիջյանի մեկնաբանությամբ (նվիրվում է Ռոսինիի «Stabat Mater»-ի ստեղծման 180-ամյակին և Հայաստանի ազգային ակադեմիական երգչախմբի հիմնադրման 85-ամյակին)
    Աննա Ասատրյան
    Journal of Art Studies.2022; : 79.     CrossRef
  • Metoclopramide, Dexamethasone, or Palonosetron for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately Emetogenic Chemotherapy (MEDEA): A Randomized, Phase III, Noninferiority Trial
    Maurice J.D.L. van der Vorst, Elisa C. Toffoli, Marlien Beusink, Myra E. van Linde, Theo van Voorthuizen, Saskia Brouwer, Annette A. van Zweeden, Suzan Vrijaldenhoven, Johan C. Berends, Johannes Berkhof, Henk M.W. Verheul
    The Oncologist.2021; 26(1): e173.     CrossRef
  • Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature
    Ronald Chow, Jørn Herrstedt, Matti Aapro, Leonard Chiu, Henry Lam, Elizabeth Prsic, Michael Lock, Carlo DeAngelis, Rudolph M. Navari
    Supportive Care in Cancer.2021; 29(7): 3439.     CrossRef
  • A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients
    Junichi Nishimura, Akiko Hasegawa, Toshihiro Kudo, Tomoyuki Otsuka, Masayoshi Yasui, Chu Matsuda, Naotsugu Haraguchi, Hajime Ushigome, Nozomu Nakai, Tomoki Abe, Hisashi Hara, Naoki Shinno, Kei Asukai, Shinichiro Hasegawa, Daisaku Yamada, Keijiro Sugimura,
    Scientific Reports.2021;[Epub]     CrossRef
  • The Balance Between the Effectiveness and Safety for Chemotherapy-Induced Nausea and Vomiting of Different Doses of Olanzapine (10 mg Versus 5 mg): A Systematic Review and Meta-Analysis
    Dong-Yang Wang, Yi Chen, You Zhang, Ying-Qiang Shen
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients
    Winnie Yeo, Thomas KH. Lau, Leung Li, Kwai Tung Lai, Elizabeth Pang, Maggie Cheung, Vicky TC. Chan, Ashley Wong, Winnie MT. Soo, Vanessa TY. Yeung, Teresa Tse, Daisy CM. Lam, Eva WM. Yeung, Kim PK. Ng, Nelson LS. Tang, Macy Tong, Joyce JS. Suen, Frankie K
    The Breast.2020; 50: 30.     CrossRef
  • RETRACTED ARTICLE: Poloxamer-407-Co-Poly (2-Acrylamido-2-Methylpropane Sulfonic Acid) Cross-linked Nanogels for Solubility Enhancement of Olanzapine: Synthesis, Characterization, and Toxicity Evaluation
    Kifayat Ullah Khan, Naveed Akhtar, Muhammad Usman Minhas
    AAPS PharmSciTech.2020;[Epub]     CrossRef
  • Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study


    Xuan Wu, Jingxun Wu, Gangling Tong, Boran Cheng, Minhua Chen, Shaokang Yu, Lirui He, Zhu Li, Shubin Wang
    Cancer Management and Research.2020; Volume 12: 6575.     CrossRef
  • Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
    So Rae Lee, Su Min Kim, Min Young Oh, Jae Min Lee
    Children.2020; 7(9): 140.     CrossRef
  • Olanzapine: The Game-Changer “Antiemetic”
    Manikandan Dhanushkodi
    Indian Journal of Medical and Paediatric Oncology.2019; 40(02): 274.     CrossRef
  • 9,410 View
  • 494 Download
  • 24 Web of Science
  • 22 Crossref
Close layer
Meta-Analysis
Adjuvant Chemotherapy for Advanced Gastric Cancer in Elderly and Non-elderly Patients: Meta-Analysis of Randomized Controlled Trials
Seong-Hwan Chang, Soo-Nyung Kim, Hye Jung Choi, Misuk Park, Rock Bum Kim, Se-Il Go, Won Sup Lee
Cancer Res Treat. 2017;49(1):263-273.   Published online July 5, 2016
DOI: https://doi.org/10.4143/crt.2016.054
AbstractAbstract PDFPubReaderePub
Purpose
This study evaluated the benefits of adjuvant chemotherapy on elderly patients with advanced gastric cancer (AGC) using meta-analysis of well-designed randomized controlled clinical studies.
Materials and Methods
PubMed, Embase, and Cochrane were searched to retrieve clinical studies evaluating the benefits of adjuvant chemotherapy in the elderly with AGC. Hazards ratios (HRs) with 95% confidence intervals (CIs) were pooled across studies using a fixed-effects model.
Results
Two studies were included in this meta-analysis to estimate HR for the overall survival (OS), and relapse-free survival (RFS) between adjuvant chemotherapy and surgery in elderly and non-elderly patients. HR for OS in the elderly and non-elderly was 0.745 (95% CI, 0.552 to 1.006, p=0.055) and 0.636 (95% CI, 0.522 to 0.776; p < 0.001), respectively, which showed no heterogeneity regarding HR between the two groups (pinteraction=0.389). HR for RFS in the elderly and non-elderly was 0.613 (95% CI, 0.466 to 0.806; p < 0.001) and 0.633 (95% CI, 0.533 to 0.753; p < 0.001), respectively (pinteraction=0.846).
Conclusion
Meta-analysis suggests that the benefit of adjuvant chemotherapy to the elderly is not big enough to reach statistical significance while the HR for OS is less than 1 (0.745) and no heterogeneity are observed regarding the HR between the elderly and non-elderly patients.

Citations

Citations to this article as recorded by  
  • State of the scientific evidence and recommendations for the management of older patients with gastric cancer
    Irene Paredero-Pérez, Paula Jimenez-Fonseca, Juana María Cano, Virginia Arrazubi, Alberto Carmona-Bayonas, Marta Covela-Rúa, Ana Fernández-Montes, Marta Martín-Richard, Regina Gironés-Sarrió
    Journal of Geriatric Oncology.2024; 15(3): 101657.     CrossRef
  • Surgical options and survival prognosis in geriatric patients beyond average lifespan with locally advanced gastric cancer: a propensity score-matched analysis
    Zhen Tian, Mingyu Xia, Yifan Cheng, Jiajie Zhou, Ruiqi Li, Shuai Zhao, Qiannan Sun, Daorong Wang
    Surgical Endoscopy.2024; 38(5): 2756.     CrossRef
  • Prognostic factors and the necessity of chemotherapy for stage II gastric cancer: a model based on multicenter retrospective study
    Jiaming Fang, Feiyang Zhang, Jun Lu, Zijian Deng, Xianzhe Li, Xijie Chen, Changming Huang, Yingbo Chen, Lei Lian, Junsheng Peng, Shi Chen
    Discover Oncology.2023;[Epub]     CrossRef
  • Adjuvant Chemotherapy in Older Patients with Gastric Cancer: A Population-Based Cohort Study
    Wing-Lok Chan, Xiaodong Liu, Carlos King-Ho Wong, Michael Siu-Nam Wong, Ian Yu-Hong Wong, Ka-On Lam, Bryan Ho-Kwan Yun, Emina Edith Cheung, Rosa Pui-Ying Tse, Fion Chan, Simon Law, Dora Kwong
    Cancers.2023; 15(15): 3768.     CrossRef
  • The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study
    Yu-Hsuan Shih, Hsin-Chen Lin, Po-Wei Liao, Cheng-Wei Chou, Cheng-Hsien Lin, Chiann-Yi Hsu, Chieh-Lin Jerry Teng, Feng-Hsu Wu, Shao-Ciao Luo, Shao-Hsuan Kao
    BMC Cancer.2023;[Epub]     CrossRef
  • Age dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction – a multicenter retrospective observational study of young versus old patients
    Ingmar F. Rompen, Nerma Crnovrsanin, Henrik Nienhüser, Kerstin Neuschütz, Lana Fourie, Leila Sisic, Beat P. Müller-Stich, Adrian T. Billeter
    International Journal of Surgery.2023;[Epub]     CrossRef
  • Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study
    Seohee Choi, Jae-Seok Min, Sang-Ho Jeong, Moon-Won Yoo, Young-Gil Son, Sung Jin Oh, Jong-Han Kim, Joong-Min Park, Hoon Hur, Ye Seob Jee, Sun-Hwi Hwang, Sung-Ho Jin, Sang Eok Lee, Young-Joon Lee, Kyung Won Seo, Sungsoo Park, Chang Min Lee, Chang Hyun Kim,
    Journal of Gastric Cancer.2022; 22(1): 67.     CrossRef
  • Considerations and Challenges in the Management of the Older Patients with Gastric Cancer
    Sotiris Loizides, Demetris Papamichael
    Cancers.2022; 14(6): 1587.     CrossRef
  • Surgical Oncology and Geriatric Patients
    Michael E. Johnston, Jeffrey J. Sussman, Sameer H. Patel
    Clinics in Geriatric Medicine.2019; 35(1): 53.     CrossRef
  • Optimal treatment for elderly patients with resectable proximal gastric carcinoma: a real world study based on National Cancer Database
    Xuefei Wang, Junjie Zhao, Mark Fairweather, Tingsong Yang, Yihong Sun, Jiping Wang
    BMC Cancer.2019;[Epub]     CrossRef
  • Thalidomide combined with chemotherapy in treating elderly patients with advanced gastric cancer
    Ya Li, Yanjun Chu, Ruifeng Song, Feng Xu
    Aging Clinical and Experimental Research.2018; 30(5): 499.     CrossRef
  • Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
    Deng-Feng Ren, Fang-Chao Zheng, Jun-Hui Zhao, Guo-Shuang Shen, Raees Ahmad, Shui-Sheng Zhang, Yu Zhang, Jie Kan, Li Dong, Zi-Yi Wang, Fu-Xing Zhao, Jiu-Da Zhao
    World Journal of Clinical Cases.2018; 6(10): 373.     CrossRef
  • Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy
    Yuhree Kim, Malcolm H. Squires, George A. Poultsides, Ryan C. Fields, Sharon M. Weber, Konstantinos I. Votanopoulos, David A. Kooby, David J. Worhunsky, Linda X. Jin, William G. Hawkins, Alexandra W. Acher, Clifford S. Cho, Neil Saunders, Edward A. Levine
    Surgery.2017; 162(2): 285.     CrossRef
  • 10,843 View
  • 259 Download
  • 14 Web of Science
  • 13 Crossref
Close layer
Original Articles
Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis
Se-Il Go, Young Saing Kim, In Gyu Hwang, Eun Young Kim, Sung Yong Oh, Jun Ho Ji, Haa-Na Song, Se Hoon Park, Joon Oh Park, Jung Hun Kang
Cancer Res Treat. 2016;48(4):1274-1285.   Published online February 12, 2016
DOI: https://doi.org/10.4143/crt.2015.502
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to assess the role of adjuvant therapy in stage I-III gallbladder cancer (GBC) patients who have undergone R0 resection.
Materials and Methods
Clinical data were collected on 441 consecutive patients who underwent R0 resection for stage I-III GBC. Eligible patients were classified into adjuvant therapy and surveillance only groups. Propensity score matching (PSM) between the two groups was performed, adjusting clinical factors.
Results
In total, 84 and 279 patients treated with adjuvant therapy and followed up with surveillance only, respectively, were included in the analysis. Before PSM, the 5-year relapse-free survival (RFS) rate was lower in the adjuvant therapy group than in the surveillance only group (50.8% vs. 74.8%, p < 0.001), although there was no statistically significant difference in the 5-year overall survival (OS) rate (66.2% vs. 79.5%, p=0.089). After the PSM, baseline characteristics became comparable and there were no differences in the 5-year RFS (50.8% vs. 64.8%, p=0.319) and OS (66.2% vs. 70.4%, p=0.703) rates between the two groups.
Conclusion
The results suggest that fluoropyrimidine-based adjuvant therapy is not indicated in stage I-III GBC patients who have undergone R0 resection.

Citations

Citations to this article as recorded by  
  • Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection
    Sundeep Singh Saluja, Phani Kumar Nekarakanti, Pramod Kumar Mishra, Anurita Srivastava, Kishore Singh
    Journal of Gastrointestinal Surgery.2022; 26(2): 398.     CrossRef
  • Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
    Xiuqiong Chen, Fanqiao Meng, Hua Xiong, Yanmei Zou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Current standards and future perspectives in adjuvant treatment for biliary tract cancers
    Angela Lamarca, Julien Edeline, Mairéad G McNamara, Richard A Hubner, Masato Nagino, John Bridgewater, John Primrose, Juan W Valle
    Cancer Treatment Reviews.2020; 84: 101936.     CrossRef
  • Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer
    Jung Ho Im, Woo Jung Lee, Chang Moo Kang, Ho Kyoung Hwang, Jinsil Seong
    HPB.2020; 22(8): 1168.     CrossRef
  • Prognostic Factors for Operated Gallbladder Cancer
    Bala Basak Oven Ustaalioglu, Ahmet Bilici, Mesut Seker, Umut Kefeli, Dincer Aydin, Serkan Celik, Tarik Demir, Burcak Erkol
    Journal of Gastrointestinal Cancer.2019; 50(3): 451.     CrossRef
  • Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer
    Abhay K. Kattepur, Shraddha Patkar, Mahesh Goel, Anant Ramaswamy, Vikas Ostwal
    Journal of Gastrointestinal Surgery.2019; 23(11): 2232.     CrossRef
  • A systematic review of the effectiveness of adjuvant therapy for patients with gallbladder cancer
    Carlos Manterola, Galo Duque, Luis Grande, Xabier de Aretxabala, Roque Conejeros, Tamara Otzen, Nayely García
    HPB.2019; 21(11): 1427.     CrossRef
  • Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis
    Byoung Hyuck Kim, Jeanny Kwon, Eui Kyu Chie, Kyubo Kim, Young Hoon Kim, Dong Wan Seo, Amol K. Narang, Joseph M. Herman
    Annals of Surgical Oncology.2018; 25(1): 255.     CrossRef
  • Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
    T Ebata, S Hirano, M Konishi, K Uesaka, Y Tsuchiya, M Ohtsuka, Y Kaneoka, M Yamamoto, Y Ambo, Y Shimizu, F Ozawa, A Fukutomi, M Ando, Y Nimura, M Nagino, S Nakamori, T Ajiki, H Baba, R Yamaguchi, M Kawai, H Nagano, F Miura, T Arai, Y Nishiwaki, S Kawasaki
    British Journal of Surgery.2018; 105(3): 192.     CrossRef
  • Adjuvant systemic therapy and postoperative outcomes after resection of node positive gallbladder cancer
    Jiong-Jie Yu, Xin-Fei Xu, Tian Yang
    International Journal of Surgery.2018; 54: 307.     CrossRef
  • The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer
    Luxi Yin, Qi Xu, Jingjing Li, Qing Wei, Jieer Ying
    Medicine.2018; 97(50): e13570.     CrossRef
  • Surgical Management of Gallbladder Cancer
    Gyulnara G. Kasumova, Omidreza Tabatabaie, Robert M. Najarian, Mark P. Callery, Sing Chau Ng, Andrea J. Bullock, Robert A. Fisher, Jennifer F. Tseng
    Annals of Surgery.2017; 266(4): 625.     CrossRef
  • 15,049 View
  • 203 Download
  • 18 Web of Science
  • 12 Crossref
Close layer
Population-Based Regional Cancer Incidence in Korea: Comparison between Urban and Rural Areas
Haa-Na Song, Se-Il Go, Won Sup Lee, Yire Kim, Hye Jung Choi, Un Seok Lee, Myoung Hee Kang, Gyeong-Won Lee, Hoon-Gu Kim, Jung Hun Kang, Yune Sik Kang, Jeong-Hee Lee, Jin-Myung Jung, Soon Chan Hong
Cancer Res Treat. 2016;48(2):789-797.   Published online July 14, 2015
DOI: https://doi.org/10.4143/crt.2015.062
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to investigate differences in organ-specific cancer incidence according to the region and population size in Korea.
Materials and Methods
We reviewed the data of the cancer registration program of Gyeongnam Regional Cancer Center between 2008 and 2011. Age-standardized rates of cancer incidence were analyzed according to population size of the region and administrative zone.
Results
Incidence of thyroid cancer has been increasing rapidly in both urban and rural areas. However, the thyroid cancer incidence was much lower in rural areas than in urban areas and megalopolis such as Seoul. Gastric cancer was relatively more common in rural areas, in megalopolis near the sea (Ulsan, Busan, and Incheon), and other southern provinces (Chungcheongnam-do, Gyeongsangbuk-do, and Gyeongsangnam-do). A detailed analysis in Gyeongsangnam-do revealed that rural areas have relatively low incidence of thyroid and colorectal cancer, and relatively high incidence of gastric and lung cancer compared to urban areas.
Conclusion
This study suggests that there are some differences in cancer incidence by population size. Thyroid and colorectal cancer incidence was increasing, and gastric and lung cancer was slightly decreasing in urban areas, whereas gastric and lung cancer incidence still remains high in rural areas.

Citations

Citations to this article as recorded by  
  • Impact of regional medical self-sufficiency on mortality from cancer, stroke and myocardial infarction
    Il Yun, Jong Youn Moon
    Public Health.2025; 238: 59.     CrossRef
  • Rural-urban disparity in cancer burden and care: findings from an Indian cancer registry
    Divya Khanna, Priyanka Sharma, Atul Budukh, Rajesh Vishwakarma, Anand N. Sharma, Sonali Bagal, Varsha Tripathi, Vijay Kumar Maurya, Pankaj Chaturvedi, Satyajit Pradhan
    BMC Cancer.2024;[Epub]     CrossRef
  • What is the relationship between the local population change and cancer incidence in patients with dyslipidemia: Evidence of the impact of local extinction in Korea
    Wonjeong Jeong, Dong‐Woo Choi, Woorim Kim, Kyu‐Tae Han
    Cancer Medicine.2024;[Epub]     CrossRef
  • Health expenditure trajectory and gastric cancer incidence in the National Health Insurance Senior Cohort: a nested case-control study
    Woo-Ri Lee, Ki-Bong Yoo, Jin-Won Noh, Minjee Lee
    BMC Health Services Research.2024;[Epub]     CrossRef
  • Projection of future gastric cancer incidence and health‐care service demand by geographic area in Kanagawa, Japan
    Choy‐Lye Chei, Sho Nakamura, Kaname Watanabe, Ryo Watanabe, Akio Kurokawa, Taizo Iwane, Sayaka Itoh, Hiroto Narimatsu
    Cancer Science.2024;[Epub]     CrossRef
  • Urban Scaling of Health Outcomes: a Scoping Review
    Edwin M. McCulley, Pricila H. Mullachery, Ana F. Ortigoza, Daniel A. Rodríguez, Ana V. Diez Roux, Usama Bilal
    Journal of Urban Health.2022; 99(3): 409.     CrossRef
  • Loss of Novel Diversity in Human Gut Microbiota Associated with Ongoing Urbanization in China
    Shan Sun, Huijun Wang, Annie Green Howard, Jiguo Zhang, Chang Su, Zhihong Wang, Shufa Du, Anthony A. Fodor, Penny Gordon-Larsen, Bing Zhang, Emily B. Graham
    mSystems.2022;[Epub]     CrossRef
  • Deciphering the impact of urban built environment density on respiratory health using a quasi-cohort analysis of 5495 non-smoking lung cancer cases
    Lan Wang, Wenyao Sun, Anne Vernez Moudon, Yong-Guan Zhu, Jinfeng Wang, Pingping Bao, Xiaojing Zhao, Xiaoming Yang, Yinghui Jia, Surong Zhang, Shuang Wu, Yuxi Cai
    Science of The Total Environment.2022; 850: 158014.     CrossRef
  • Difference in medical service use among Korean gastric cancer survivors according to regional healthcare vulnerabilities: a cohort study
    Sung Hoon Jeong, Jae Hong Joo, Minah Park, Choa Yun, Soo Hyun Kang, Eun-Cheol Park, Yoon Dae Han, Sung-In Jang
    Supportive Care in Cancer.2022; 30(11): 9233.     CrossRef
  • Apoptotic Effects of Anthocyanins from Vitis coignetiae Pulliat Are Enhanced by Augmented Enhancer of the Rudimentary Homolog (ERH) in Human Gastric Carcinoma MKN28 Cells
    Cheol Park, Won Sup Lee, Se-Il Go, Sang-Ho Jeong, Jiyun Yoo, Hee-Jae Cha, Young-Joon Lee, Heui-Soo Kim, Sun-Hee Leem, Hye Jung Kim, Gon Sup Kim, Soon-Chan Hong, Yung Hyun Choi
    International Journal of Molecular Sciences.2021; 22(6): 3030.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Impact of Rurality on National Trends in Thyroid Cancer Incidence and Long‐Term Survival
    Alexandria D. McDow, Whitney E. Zahnd, Peter Angelos, John D. Mellinger, Sabha Ganai
    The Journal of Rural Health.2020; 36(3): 326.     CrossRef
  • Predicted Future Mortality Attributed to Increases in Temperature and PM10 Concentration under Representative Concentration Pathway Scenarios
    Jiyun Jung, Jae Young Lee, Hyewon Lee, Ho Kim
    International Journal of Environmental Research and Public Health.2020; 17(7): 2600.     CrossRef
  • Polyphenols Extracted from Artemisia annua L. Exhibit Anti-Cancer Effects on Radio-Resistant MDA-MB-231 Human Breast Cancer Cells by Suppressing Stem Cell Phenotype, β-Catenin, and MMP-9
    Young Shin Ko, Eun Joo Jung, Se-il Go, Bae Kwon Jeong, Gon Sup Kim, Jin-Myung Jung, Soon Chan Hong, Choong Won Kim, Hye Jung Kim, Won Sup Lee
    Molecules.2020; 25(8): 1916.     CrossRef
  • Temporal and geographical variations in colorectal cancer incidence in Northern Iran 2004–2013
    Susan Hasanpour-Heidari, Abdolreza Fazel, Shahryar Semnani, Seyyed-Reza Khandoozi, Taghi Amiriani, SeyedMehdi Sedaghat, Reza Hosseinpoor, Ramin Azarhoush, Mohammad Poorabbasi, Mohammad Naeimi-Tabiei, Gholamreza Roshandel, Freddie Bray, Elisabete Weiderpas
    Cancer Epidemiology.2019; 59: 143.     CrossRef
  • Regional Differences in Years of Life Lost in Korea from 1997 to 2015
    Dun-Sol Go, Young-Eun Kim, Munkhzul Radnaabaatar, Yunsun Jung, Jaehun Jung, Seok-Jun Yoon
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Morin enhances auranofin anticancer activity by up‐regulation of DR4 and DR5 and modulation of Bcl‐2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells
    Hyun Hwang‐Bo, Won Sup Lee, Arulkumar Nagappan, Hong Jae Kim, Radha Panchanathan, Cheol Park, Seong‐Hwan Chang, Nam Deuk Kim, Sun‐Hee Leem, Young‐Chae Chang, Taeg Kyu Kwon, Jae Hun Cheong, Gon Sup Kim, Jin‐Myung Jung, Sung Chul Shin, Soon Chan Hong, Yung
    Phytotherapy Research.2019; 33(5): 1384.     CrossRef
  • The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer
    Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
    Cancer Research and Treatment.2019; 51(4): 1411.     CrossRef
  • Cancer Incidence Trend in the Hebei Spirit Oil Spill Area, from 1999 to 2014: An Ecological Study
    Kyung-Hwa Choi, Myung-Sook Park, Mina Ha, Jong-Il Hur, Hae-Kwan Cheong
    International Journal of Environmental Research and Public Health.2018; 15(5): 1006.     CrossRef
  • Gut Microbiota in Tibetan Herdsmen Reflects the Degree of Urbanization
    Huan Li, Tongtong Li, Xiangzhen Li, Guanhong Wang, Qiang Lin, Jiapeng Qu
    Frontiers in Microbiology.2018;[Epub]     CrossRef
  • Regional Differences in Years of Life Lost in Korea from 1997 to 2015
    Dun-Sol Go, Young-Eun Kim, Munkhzul Radnaabaatar, Yunsun Jung, Jaehun Jung, Seok-Jun Yoon
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Estimation of the Incidence of Hepatocellular Carcinoma and Cholangiocarcinoma in Songkhla, Thailand, 1989-2013, Using Multiple Imputation Method
    Seesai Yeesoonsang, Surichai Bilheem, Edward McNeil, Sophon Iamsirithaworn, Chuleeporn Jiraphongsa, Hutcha Sriplung
    Cancer Research and Treatment.2017; 49(1): 54.     CrossRef
  • Prognostic impact of Ki-67 in patients with gastric cancer—the importance of depth of invasion and histologic differentiation
    Gyung Hyuck Ko, Se-Il Go, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
    Medicine.2017; 96(25): e7181.     CrossRef
  • Recent urbanization in China is correlated with a Westernized microbiome encoding increased virulence and antibiotic resistance genes
    Kathryn Winglee, Annie Green Howard, Wei Sha, Raad Z. Gharaibeh, Jiawu Liu, Donghui Jin, Anthony A. Fodor, Penny Gordon-Larsen
    Microbiome.2017;[Epub]     CrossRef
  • 12,751 View
  • 110 Download
  • 25 Web of Science
  • 24 Crossref
Close layer
CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer
Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Rock Bum Kim, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
Cancer Res Treat. 2016;48(1):142-152.   Published online March 17, 2015
DOI: https://doi.org/10.4143/crt.2014.227
AbstractAbstract PDFPubReaderePub
Purpose
The present study is to investigate the significance of CD44 variant 9 (CD44v9) expression as a biomarker in primary gastric cancer.
Materials and Methods
With various gastric tissues, we performed immunohistochemical staining for CD44v9.
Results
The positive expression rates for CD44v9 in tumor, including adenoma, early gastric cancer (EGC), and advanced gastric cancer (AGC), were higher than those in non-tumor tissues (p = 0.003). In addition, the higher expression for CD44v9 was observed as the tissue becomes malignant. In the analysis of 333 gastric cancer tissues, we found that positive expression rates for CD44v9 were higher in the intestinal type or well differentiated gastric cancer than in the diffuse type or poorly differentiated gastric cancer. Interestingly, the positive expression indicated poor prognosis in EGC (5-YSR in stage I, 81.7% vs 95.2%; p = 0.013), but not in AGC (5-YSR in stage II, 66.9% vs 62.2%; p = 0.821, 5-YSR in stage III, 34.5% vs 32.0%; p = 0.929). Moreover, strong positive expression (3+) showed a trend suggesting worse prognosis only in EGC, and it appeared to be associated with lymph node metastasis.
Conclusion
This study suggests that CD44v9 may be a good biomarker for prognosis prediction and for chemoprevention or biomarker-driven therapies only for EGC.

Citations

Citations to this article as recorded by  
  • Single-cell RNA-seq reveals MIF−(CD74 + CXCR4) dependent inhibition of macrophages in metastatic papillary thyroid carcinoma
    Wei Chen, Xinnian Yu, Huixin Li, Shenglong Yuan, Yuqi Fu, Huanhuan Hu, Fangzhou Liu, Yuan Zhang, Shanliang Zhong
    Oral Oncology.2024; 148: 106654.     CrossRef
  • Can Nano Yield Big Insights? Oligonucleotide-Based Biosensors in Early Diagnosis of Gastric Cancer
    Alexandra E. Avanu, Alexandra M. Ciubotariu, Gianina Dodi
    Chemosensors.2024; 12(3): 44.     CrossRef
  • Diagnostic and prognostic value of CD44v9 and TIM3 expression in CK‑ and CK+ regions in gastric cancer tissues
    Xiaofei Wang, Lin Lu, Ruidong Yang, Zhiwu Wang, Qingke Li, Jingwu Li, Yankun Liu
    Oncology Letters.2024;[Epub]     CrossRef
  • Late recurrent gastric carcinoma 12 years after surgery with attenuation of CD44 variant 9 expression
    Hirokatsu Hayashi, Itaru Yasufuku, Toshiya Higashi, Wakana Chikaishi, Ryoma Yokoi, Masahiro Fukada, Yuta Sato, Ryuichi Asai, Jesse Yu Tajima, Chiemi Saigo, Akitaka Makiyama, Yoshihiro Tanaka, Naoki Okumura, Katsutoshi Murase, Takao Takahashi, Manabu Futam
    Surgical Case Reports.2023;[Epub]     CrossRef
  • The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer
    Nicola Cirillo
    International Journal of Molecular Sciences.2023; 24(21): 15812.     CrossRef
  • Cyclin D1 Serves as a Poor Prognostic Biomarker in Stage I Gastric Cancer
    Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
    Current Issues in Molecular Biology.2022; 44(3): 1395.     CrossRef
  • Molecular pathogenesis and emerging targets of gastric adenocarcinoma
    Abby Ivey, Hillary Pratt,  Brian A. Boone
    Journal of Surgical Oncology.2022; 125(7): 1079.     CrossRef
  • Clinical and prognostic significances of cancer stem cell markers in gastric cancer patients: a systematic review and meta-analysis
    Mahdieh Razmi, Roya Ghods, Somayeh Vafaei, Maryam Sahlolbei, Leili Saeednejad Zanjani, Zahra Madjd
    Cancer Cell International.2021;[Epub]     CrossRef
  • CD44 polymorphisms and its variants, as an inconsistent marker in cancer investigations
    Mohammad Mahmoudi Gomari, Marziye Farsimadan, Neda Rostami, Zahra mahmoudi, Mahmood Fadaie, Ibrahim Farhani, Parastoo Tarighi
    Mutation Research/Reviews in Mutation Research.2021; : 108374.     CrossRef
  • Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation
    Tomoko Jogo, Eiji Oki, Ryota Nakanishi, Koji Ando, Yuichiro Nakashima, Yasue Kimura, Hiroshi Saeki, Yoshinao Oda, Yoshihiko Maehara, Masaki Mori
    Gastric Cancer.2021; 24(5): 1089.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer
    Luis Enrique Cortés-Hernández, Zahra Eslami-S, Catherine Alix-Panabières
    Molecular Aspects of Medicine.2020; 72: 100816.     CrossRef
  • Decrease in MiR-148a Expression During Initiation of Chief Cell Transdifferentiation
    Takahiro Shimizu, Yoojin Sohn, Eunyoung Choi, Christine P. Petersen, Nripesh Prasad, James R. Goldenring
    Cellular and Molecular Gastroenterology and Hepatology.2020; 9(1): 61.     CrossRef
  • Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer
    Jie Yang
    Medical Oncology.2020;[Epub]     CrossRef
  • Trop2 is upregulated in the transition to dysplasia in the metaplastic gastric mucosa
    Katherine M Riera, Bogun Jang, Jimin Min, Joseph T Roland, Qing Yang, William T Fesmire, Sophie Camilleri‐Broet, Lorenzo Ferri, Woo H Kim, Eunyoung Choi, James R Goldenring
    The Journal of Pathology.2020; 251(3): 336.     CrossRef
  • Prognostic value of CD44v9 expression in human cancers: Retraction
    Li Zeng, Yitian Chen, Ligang Chen, Chengwei Tang
    Medicine.2020; 99(30): e20428.     CrossRef
  • Roles of Proteoglycans and Glycosaminoglycans in Cancer Development and Progression
    Jinfen Wei, Meiling Hu, Kaitang Huang, Shudai Lin, Hongli Du
    International Journal of Molecular Sciences.2020; 21(17): 5983.     CrossRef
  • The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation
    Takaki Akamine, Tetsuzo Tagawa, Kayo Ijichi, Gouji Toyokawa, Shinkichi Takamori, Fumihiko Hirai, Tatsuro Okamoto, Yoshinao Oda, Yoshihiko Maehara
    Annals of Surgical Oncology.2019; 26(5): 1544.     CrossRef
  • Cancer Stem-Cell Marker CD44v9-Positive Cells Arise From Helicobacter pylori–Infected CAPZA1-Overexpressing Cells
    Hitoshi Tsugawa, Chihiro Kato, Hideki Mori, Juntaro Matsuzaki, Kaori Kameyama, Hideyuki Saya, Masanori Hatakeyama, Makoto Suematsu, Hidekazu Suzuki
    Cellular and Molecular Gastroenterology and Hepatology.2019; 8(3): 319.     CrossRef
  • hnRNPK promotes gastric tumorigenesis through regulating CD44E alternative splicing
    Wei-zhao Peng, Ji-xi Liu, Chao-feng Li, Ren Ma, Jian-zheng Jie
    Cancer Cell International.2019;[Epub]     CrossRef
  • The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer
    Se-Il Go, Gyung Hyuck Ko, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
    Cancer Research and Treatment.2019; 51(4): 1411.     CrossRef
  • Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer
    Masayuki Hagiwara, Eiji Kikuchi, Nobuyuki Tanaka, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, Mototsugu Oya
    BMC Cancer.2018;[Epub]     CrossRef
  • Glutamate-cysteine ligase catalytic subunit is associated with cisplatin resistance in lung adenocarcinoma
    Noriko Hiyama, Takahiro Ando, Keita Maemura, Toshio Sakatani, Yosuke Amano, Kousuke Watanabe, Hidenori Kage, Yutaka Yatomi, Takahide Nagase, Jun Nakajima, Daiya Takai
    Japanese Journal of Clinical Oncology.2018; 48(4): 303.     CrossRef
  • Overexpression of CD44 Variant 9: A Novel Cancer Stem Cell Marker in Human Cholangiocarcinoma in Relation to Inflammation
    Nattawan Suwannakul, Ning Ma, Raynoo Thanan, Somchai Pinlaor, Piti Ungarreevittaya, Kaoru Midorikawa, Yusuke Hiraku, Shinji Oikawa, Shosuke Kawanishi, Mariko Murata
    Mediators of Inflammation.2018; 2018: 1.     CrossRef
  • Expression of CD44, CD44v9, ABCG2, CD24, Bmi‑1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological factors
    Tetsuya Tamatani, Natsumi Takamaru, Go Ohe, Kazuya Akita, Takayuki Nakagawa, Youji Miyamoto
    Oncology Letters.2018;[Epub]     CrossRef
  • Hyaluronic acid in digestive cancers
    Ruo-Lin Wu, Lei Huang, Hong-Chuan Zhao, Xiao-Ping Geng
    Journal of Cancer Research and Clinical Oncology.2017; 143(1): 1.     CrossRef
  • Prognostic impact of Ki-67 in patients with gastric cancer—the importance of depth of invasion and histologic differentiation
    Gyung Hyuck Ko, Se-Il Go, Won Sup Lee, Jeong-Hee Lee, Sang-Ho Jeong, Young-Joon Lee, Soon Chan Hong, Woo Song Ha
    Medicine.2017; 96(25): e7181.     CrossRef
  • Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)
    Kohei Shitara, Toshihiko Doi, Osamu Nagano, Chiyo K. Imamura, Takeshi Ozeki, Yuya Ishii, Kenji Tsuchihashi, Shunji Takahashi, Takako E. Nakajima, Shuichi Hironaka, Miki Fukutani, Hiromi Hasegawa, Shogo Nomura, Akihiro Sato, Yasuaki Einaga, Takeshi Kuwata,
    Gastric Cancer.2017; 20(2): 341.     CrossRef
  • CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues
    Yushi YAMAKAWA, Masatoshi KUSUHARA, Masanori TERASHIMA, Yusuke KINUGASA, Takashi SUGINO, Masato ABE, Toru MOCHIZUKI, Keiichi HATAKEYAMA, Kenjiro KAMI, Ken YAMAGUCHI
    Biomedical Research.2017; 38(1): 41.     CrossRef
  • Initiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells
    Yana Zavros
    Cellular and Molecular Gastroenterology and Hepatology.2017; 4(1): 55.     CrossRef
  • Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)
    Kohei Shitara, Toshihiko Doi, Osamu Nagano, Miki Fukutani, Hiromi Hasegawa, Shogo Nomura, Akihiro Sato, Takeshi Kuwata, Kai Asai, Yasuaki Einaga, Kenji Tsuchihashi, Kentaro Suina, Yusuke Maeda, Hideyuki Saya, Atsushi Ohtsu
    Gastric Cancer.2017; 20(6): 1004.     CrossRef
  • Hypoxia regulates CD44 expression via hypoxia-inducible factor-1α in human gastric cancer cells
    Gai Liang, Shuang Li, Wei Du, Qinghua Ke, Jun Cai, Jiyuan Yang
    Oncology Letters.2017; 13(2): 967.     CrossRef
  • Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality
    Masayuki Hagiwara, Eiji Kikuchi, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, Mototsugu Oya
    Urologic Oncology: Seminars and Original Investigations.2016; 34(8): 337.e19.     CrossRef
  • Cancer stem cells in human digestive tract malignancies
    Fatemeh B. Rassouli, Maryam M. Matin, Morvarid Saeinasab
    Tumor Biology.2016; 37(1): 7.     CrossRef
  • 13,961 View
  • 123 Download
  • 38 Web of Science
  • 34 Crossref
Close layer
Case Report
Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission
Won Sup Lee, Ji-Hyen Hwang, Moon Jin Kim, Se-Il Go, Anna Lee, Haa-Na Song, Min Jeong Lee, Myung Hee Kang, Hoon-Gu Kim, Jeong-Hee Lee
Cancer Res Treat. 2014;46(3):312-316.   Published online July 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.3.312
AbstractAbstract PDFPubReaderePub
Subcutaneous panniculitis-like T cell lymphoma (SPTL) is a distinctive cutaneous lymphoma characterized by an infiltration of subcutaneous tissue by neoplastic T cells, similar to panniculitis. It is well-established that patients who are diagnosed with SPTL usually respond poorly to chemotherapy, showing fatal outcome. As a first line treatment for SPTL, anthracycline-based chemotherapy was most frequently used. For the treatment of SPTL, the efficacy of cyclosporine A has been recently reported in relapsed SPTL after anthracycline-based chemotherapy. However, it is still not clear whether cyclosporine A can be used as a first-line treatment against SPTL. Here, we report a case of SPTL, which achieved complete remission for nine years after first-line cyclosporine A therapy. This study suggests that cyclosporine A can induce a complete long-term remission as a first-line treatment.

Citations

Citations to this article as recorded by  
  • The pathophysiology and current treatments for the subcutaneous panniculitis‐like T cell lymphoma: An updated review
    En‐Cheng Lin, Jia‐Bin Liao, Yu‐Han Fang, Chien‐Hui Hong
    Asia-Pacific Journal of Clinical Oncology.2023; 19(1): 27.     CrossRef
  • A retrospective study of 18 children with subcutaneous panniculitis-like T-cell lymphoma: multidrug combination chemotherapy or immunomodulatory therapy?
    Yanlong Duan, Huixia Gao, Chunju Zhou, Ling Jin, Jing Yang, Shuang Huang, Meng Zhang, Yonghong Zhang, Tianyou Wang
    Orphanet Journal of Rare Diseases.2022;[Epub]     CrossRef
  • Case Report—Indurated Plaques and Recurrent Fevers in a 37-Year-Old Man: Answer
    Elizabeth Dao, Alexandra Bourgeois, Pamela Martin
    The American Journal of Dermatopathology.2021; 43(10): 754.     CrossRef
  • Hemophagocytic Lymphohistiocytosis as the Initial Presentation of Subcutaneous Panniculitis-Like T-Cell Lymphoma: A Rare Case Responding to Cyclosporine A and Steroids
    Caitlin Sullivan, Arya Loghmani, Katharine Thomas, Rachna Jetly-Shridhar, Rajasree Pia Chowdry
    Journal of Investigative Medicine High Impact Case Reports.2020;[Epub]     CrossRef
  • Rare Cutaneous T-Cell Lymphomas
    Fabiana Damasco, Oleg E. Akilov
    Hematology/Oncology Clinics of North America.2019; 33(1): 135.     CrossRef
  • Hematopoietic stem cell transplantation for subcutaneous panniculitis-like T-cell lymphoma: single center experience in an Asian population
    Ting-An Lin, Ching-Fen Yang, Yao-Chung Liu, Jin-Hwang Liu, Tzeon-jye Chiou, Liang-Tsai Hsiao, Hsiu-Ju Yen, Chia-Jen Liu, Hao-Yuan Wang, Po-Shen Ko, Sheng-Hsuan Chien, Jyh-Pyng Gau
    International Journal of Hematology.2019; 109(2): 187.     CrossRef
  • Successful treatment of a rare subcutaneous panniculitis‐like T‐cell lymphoma: An unusual case report and literature review
    Liye Xu, Yuxuan Che, Xiaolei Ding, Jincheng Song, Xian Zhang, Xiuhua Sun
    Dermatologic Therapy.2019;[Epub]     CrossRef
  • British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018
    J. Berth‐Jones, L.S. Exton, E. Ladoyanni, M.F. Mohd Mustapa, V.M. Tebbs, P.D. Yesudian, N.J. Levell, P.M. McHenry, T.A. Leslie, S. Wakelin, R.Y.P. Hunasehally, M. Cork, G.A. Johnston, N. Chiang, F.S. Worsnop, A. Salim, D. Buckley, G. Petrof, N. Callachand
    British Journal of Dermatology.2019; 180(6): 1312.     CrossRef
  • A Systematic Approach to the Cutaneous Lymphoid Infiltrates: A Clinical, Morphologic, and Immunophenotypic Evaluation
    Alejandro A. Gru, Chauncey McHargue, Andrea L. Salavaggione
    Archives of Pathology & Laboratory Medicine.2019; 143(8): 958.     CrossRef
  • Hemophagocytic lymphohistiocytosis: A rare, potentially fatal complication in subcutaneous panniculitis like T cell lymphoma
    ChandraSekhar Sirka, Swetalina Pradhan, Susama Patra, Somanath Padhi, SarojKumar DasMajumdar, Debjani Panda
    Indian Journal of Dermatology, Venereology and Leprology.2019; 85(5): 481.     CrossRef
  • Biological and clinical significance of tryptophan-catabolizing enzymes in cutaneous T-cell lymphomas
    Pilvi Maliniemi, Kirsi Laukkanen, Liisa Väkevä, Katja Dettmer, Tuomas Lipsanen, Leila Jeskanen, Alban Bessede, Peter J. Oefner, Marshall E. Kadin, Annamari Ranki
    OncoImmunology.2017; 6(3): e1273310.     CrossRef
  • Uncommon Variants of T-Cell Lymphomas
    Neha Mehta-Shah, Steven Horwitz
    Hematology/Oncology Clinics of North America.2017; 31(2): 285.     CrossRef
  • Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review
    Chi-Ching Chen, Chieh-Lin Teng, Su-Peng Yeh
    Annals of Hematology.2016; 95(5): 837.     CrossRef
  • Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides
    Meenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, Patricia L. Myskowski, Alison Moskowitz, Steven M. Horwitz
    Current Hematologic Malignancy Reports.2016; 11(3): 224.     CrossRef
  • Zebras and hen's teeth: recognition and management of rare T and NK lymphomas
    Neha Mehta–Shah, Steven Horwitz
    Hematology.2015; 2015(1): 545.     CrossRef
  • 11,382 View
  • 90 Download
  • 16 Web of Science
  • 15 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP